Biodexa Pharmaceuticals (STU:5MP2) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5MP2 Biodexa Pharmaceuticals PLC STU:5MP2
10 GF Score
Price €110,400.00
GF Value €95,593.41
! 1 Warning Sign
View Full Analysis

What is Biodexa Pharmaceuticals Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

STU:5MP2
10GF Score
Biodexa Pharmaceuticals PLC STU:5MP2
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biodexa Pharmaceuticals (STU:5MP2) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of €110,400.00 is trading 15.5% above its estimated GF Value™ of €95,593.41.

Key valuation signals for STU:5MP2:

  • Total Noninterest Expense:
  • GF Value™: €95,593.41 vs. price of €110,400.00 (15.5% above fair value)
  • GF Score™: 10/100 with 1 warning sign

No single metric tells the full story. See the STU:5MP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biodexa Pharmaceuticals Business Description

Other Exchanges BDRX:USA
Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
10GF Score

Get the complete analysis for STU:5MP2

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€110,400.00
Price
€95,593.41
GF Value